

NCT03260881 comparison:

Summary:
CHIA has 17 criteria while your personal folder has 17 criteria
Total found criteria: 17/17
Total not Found: 0/17
Total Extra: 1
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ T2DM as defined by American Diabetes Association   │ T2DM as defined by American Diabetes Association   │
│ (ADA) criteria                                     │ (ADA) criteria                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Adult patients with T2DM who are indicated to      │ Adult patients with T2DM who are indicated to      │
│ receive liraglutide, not as first-line therapy, in │ receive liraglutide, not as first-line therapy, in │
│ addition to diet and exercise to improve glycemic  │ addition to diet and exercise to improve glycemic  │
│ control                                            │ control                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hemoglobin A1c (HbA1c) = 9%                        │ Hemoglobin A1c (HbA1c) ≤ 9%                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Age = 18 years old                                 │ Age ≥ 18 years old                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Body mass index (BMI) = 27 Kg/m2 and/or waist      │ Body mass index (BMI) ≥ 27 Kg/m2 and/or waist      │
│ circumference = 102 cm (40 inches) in men and 88   │ circumference ≥ 102 cm (40 inches) in men and 88   │
│ cm (35 inches) in women, respectively              │ cm (35 inches) in women, respectively              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Clinically and angiographically stable CAD who     │ Clinically and angiographically stable CAD who     │
│ requires CABG as part of the standard medical      │ requires CABG as part of the standard medical      │
│ care, as CAD does not represent a contraindication │ care, as CAD does not represent a contraindication │
│ for using liraglutide. The stability of the CAD    │ for using liraglutide. The stability of the CAD    │
│ further warranties that study patients will not be │ further warranties that study patients will not be │
│ exposed to higher risk by using liraglutide        │ exposed to higher risk by using liraglutide        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with a personal or family history of      │ Patients with a personal or family history of      │
│ medullary thyroid carcinoma or patients with       │ medullary thyroid carcinoma or patients with       │
│ Multiple Endocrine Neoplasia syndrome type 2       │ Multiple Endocrine Neoplasia syndrome type 2       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with a prior serious hypersensitivity     │ Patients with a prior serious hypersensitivity     │
│ reaction to liraglutide                            │ reaction to liraglutide                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Other contra-indications to liraglutide in         │ Other contra-indications to liraglutide in         │
│ accordance with risks and safety information       │ accordance with risks and safety information       │
│ included in the latest updated prescribing         │ included in the latest updated prescribing         │
│ information                                        │ information                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Type 1 diabetes, as defined by ADA criteria        │ Type 1 diabetes, as defined by ADA criteria        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current use of other GLP-1A, dipeptidyl peptidase  │ Current use of other GLP-1A, dipeptidyl peptidase  │
│ 4 (DPP4) or Sodium Glucose transporters 2 (SGLT2)  │ 4 (DPP4) or Sodium Glucose transporters 2 (SGLT2)  │
│ inhibitors, thiazolidinediones (TZDs), pramlintide │ inhibitors, thiazolidinediones (TZDs), pramlintide │
│ and fixed prandial insulin                         │ and fixed prandial insulin                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with unstable CAD, assessed by the        │ Patients with unstable CAD, assessed by the        │
│ Cardiology team and defined as new onset angina,   │ Cardiology team and defined as new onset angina,   │
│ rest angina, rapidly increasing or crescendo       │ rest angina, rapidly increasing or crescendo       │
│ angina                                             │ angina                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of diabetic ketoacidosis, pancreas or      │ History of diabetic ketoacidosis, pancreas or      │
│ beta-cell transplantation, or diabetes secondary   │ beta-cell transplantation, or diabetes secondary   │
│ to pancreatitis or pancreatectomy; acute or        │ to pancreatitis or pancreatectomy; acute or        │
│ chronic infective diseases, cancer or              │ chronic infective diseases, cancer or              │
│ chemotherapy, history of pulmonary, renal or liver │ chemotherapy, history of pulmonary, renal or liver │
│ diseases, and drug abuse                           │ diseases, and drug abuse                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with chronic and acute inflammatory       │ Patients with chronic and acute inflammatory       │
│ conditions such as sepsis, rheumatoid arthritis,   │ conditions such as sepsis, rheumatoid arthritis,   │
│ ectopic dermatitis, asthma, ulcerative colitis     │ ectopic dermatitis, asthma, ulcerative colitis     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current use of systemic corticosteroids in the 3   │ Current use of systemic corticosteroids in the 3   │
│ months prior this study                            │ months prior this study                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pregnant or breast-feeding women                   │ Pregnant or breast-feeding women                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Females of childbearing potential who are not      │ Females of childbearing potential who are not      │
│ using adequate contraceptive methods (as required  │ using adequate contraceptive methods (as required  │
│ by local law or practice)                          │ by local law or practice)                          │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have minimum age of 18 Years │
╘═══════════════════════════════════╛